PATTERNS OF CLINICAL MANAGEMENT AND RESOURCE UTILIZATION FOR POSTMENOPAUSAL HORMONE-RECEPTOR-POSITIVE HER2-NEGATIVE (HR+HER2-) ADVANCED BREAST CANCER (ABC) IN EUROPE

被引：0
|
作者：
Jerusalem, G. [1 ]
Marinsek, N. [2 ]
Ricci, J. [3 ]
Etchberger, J. [2 ]
Degun, R. [2 ]
Benelli, G. [4 ]
Saletan, S. [5 ]
Andre, F. [6 ]
机构：
[1] CHU Sart Tilman, B-4000 Liege, Belgium
[2] Navigant Consulting Inc, London, England
[3] Wellmera AG, Basel, Switzerland
[4] Novartis Farma Spa, Saronno, Italy
[5] Novartis Pharmaceut, Onco Ex Dir Clin Res Phys, E Hanover, NJ USA
[6] Inst Gustave Roussy, Breast Canc Unit, Villejuif, France
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：122 / 122
页数：1
相关论文
共 50 条
  • [1] PATTERNS OF CLINICAL MANAGEMENT AND RESOURCE UTILIZATION FOR POSTMENOPAUSAL HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE (HR+HER2-) ADVANCED BREAST CANCER (ABC) IN EUROPE
    Andre, F.
    Marinsek, N.
    Ricci, J. F.
    Etchberger, J.
    Degun, R.
    Benelli, G.
    Saletan, S.
    Jerusalem, G.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A419 - A419
  • [2] Patterns of resource utilization and cost for postmenopausal women with hormone-receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) in Europe.
    Jerusalem, Guy Heinrich Maria
    Neven, Patrick
    Marinsek, Nina
    Zhang, Jie
    Degun, Ravi
    Benelli, Giancarlo
    Saletan, Stephen
    Andre, Fabrice
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] HEALTH OUTCOME GAINS AND COSTS OFFSET ASSOCIATED WITH EVEROLIMUS FOR THE TREATMENT OF HORMONE-RECEPTOR-POSITIVE (HR+) HER2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC)
    Taylor, M.
    Lewis, L.
    Vieira, J.
    Ricci, J. F.
    Chandiwana, D.
    Saletan, S.
    Sahmoud, T.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A427 - A427
  • [4] Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer
    Joseph Gligorov
    Jean-Pierre Lotz
    [J]. Breast Cancer Research and Treatment, 2008, 112 : 53 - 66
  • [5] Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer
    Gligorov, Joseph
    Lotz, Jean-Pierre
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2008, 112 (Suppl 1) : 53 - 66
  • [6] Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
    Ditsch, Nina
    Schmidt, Marcus
    [J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2019, 79 (12) : 1328 - 1335
  • [7] First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC)
    Hortobagyi, G. N.
    Stemmer, S. M.
    Burris, H. A.
    Yap, Y. S.
    Sonke, G. S.
    Paluch-Shimon, S.
    Campone, M.
    Blackwell, K.
    Andre, F.
    Winer, E. P.
    Janni, W.
    Verma, S.
    Conte, P.
    Arteaga, C. L.
    Cameron, D.
    Xuan, F.
    Souami, F.
    Miller, M.
    Germa, C.
    O'Shaughnessy, J.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [8] Detection of plasma tumor DNA (ptDNA) in patients with hormone receptor-positive HER2-negative (HR+HER2-) early breast cancer (EBC) in clinical remission
    Shah, M.
    Hunter, N.
    Ensminger, J.
    Shinn, D.
    Cole, A. J.
    Quinn, H. E.
    Edelstein, D. L.
    Wang, C.
    Smith, K. L.
    Richardson, A. L.
    Cimino-Mathews, A.
    Wolff, A. C.
    Cravero, K.
    Park, B. H.
    Stearns, V.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [9] Bosutinib and exemestane (EXE) versus EXE alone in postmenopausal (postm) women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (ABC).
    Moy, B.
    Lebrun, F.
    Bellet, M.
    Chow, L.
    Lang, I.
    Xu, B.
    Badwe, R. A.
    Hershman, D. L.
    Leip, E.
    Bardy-Bouxin, N.
    Duvillie, L.
    Neven, P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Patterns of disease management for European postmenopausal women with hormone-receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer
    Marinsek, N.
    Andre, F.
    Neven, P.
    Zhang, J.
    Degun, R.
    Benelli, G.
    Saletan, S.
    Jerusalem, G.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S411 - S411
12345